Danske Bank A S Cuts Stake in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Danske Bank A/S slashed its stake in Aurinia Pharmaceuticals by 95.3% in the fourth quarter, selling 72,820 shares and retaining just 3,600 shares worth about $57,000.
• Director Kevin Tang purchased 516,439 shares at an average price of $13.99 on Feb. 27, boosting his holdings to 11,845,939 shares (roughly $165.7M) — a 4.56% increase in his position.
• Aurinia beat expectations in its most recent quarter with EPS $0.25 vs. $0.18 and $77.7M revenue, while analysts maintain a "Moderate Buy" consensus with an average price target of $17.25 as shares trade near $15.14 (down ~6.8%).

Danske Bank A S reduced its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 95.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,600 shares of the biotechnology company's stock after selling 72,820 shares during the quarter. Danske Bank A S's holdings in Aurinia Pharmaceuticals were worth $57,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AUPH. Royal Bank of Canada grew its holdings in Aurinia Pharmaceuticals by 65.3% in the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company's stock worth $2,956,000 after purchasing an additional 145,179 shares during the last quarter. AQR Capital Management LLC grew its holdings in Aurinia Pharmaceuticals by 8.7% in the first quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company's stock worth $4,048,000 after purchasing an additional 40,380 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Aurinia Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company's stock worth $642,000 after purchasing an additional 3,497 shares during the last quarter. Creative Planning grew its holdings in Aurinia Pharmaceuticals by 21.0% in the second quarter. Creative Planning now owns 20,699 shares of the biotechnology company's stock worth $175,000 after purchasing an additional 3,594 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Aurinia Pharmaceuticals by 16.5% in the second quarter. Legal & General Group Plc now owns 141,492 shares of the biotechnology company's stock worth $1,201,000 after purchasing an additional 20,027 shares during the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, May 1st. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $17.25.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 516,439 shares of the firm's stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average cost of $13.99 per share, for a total transaction of $7,224,981.61. Following the completion of the transaction, the director directly owned 11,845,939 shares of the company's stock, valued at approximately $165,724,686.61. This trade represents a 4.56% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 12.20% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Trading Down 6.8%

NASDAQ AUPH opened at $15.14 on Friday. The company has a market capitalization of $1.97 billion, a PE ratio of 7.28 and a beta of 1.44. The company has a fifty day moving average of $15.12 and a 200 day moving average of $14.96. Aurinia Pharmaceuticals Inc has a 1 year low of $7.28 and a 1 year high of $16.88. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.25 and a quick ratio of 4.76.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Monday, May 11th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.07. The company had revenue of $77.71 million during the quarter, compared to the consensus estimate of $76.98 million. Aurinia Pharmaceuticals had a net margin of 101.46% and a return on equity of 27.47%. Research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.81 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.